Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Brain Neoplasms 635Glioblastoma 566Glioma 405Neuroblastoma 174Neoplasms 123Astrocytoma 106Central Nervous System Neoplasms 103Medulloblastoma 87Breast Neoplasms 86Meningioma 82Carcinoma, Non-Small-Cell Lung 78Melanoma 77Lung Neoplasms 69Sarcoma 66Ependymoma 64Neurofibromatosis 1 63Recurrence 50Oligodendroglioma 48Neoplasm Metastasis 48Osteosarcoma 47Meningeal Carcinomatosis 46Rhabdomyosarcoma 45Diffuse Intrinsic Pontine Glioma 44Pheochromocytoma 43Rhabdoid Tumor 41Paraganglioma 41Gliosarcoma 40Sarcoma, Ewing 39Pancreatic Neoplasms 39Colorectal Neoplasms 33

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × CNS × 1 year × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡